Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

Cancer Prevention Pharmaceuticals,Inc.
Posted on: 21 Nov 17

Cancer Prevention Pharmaceuticals (CPP), a clinical stage biotechnology company, today announced it will give a corporate presentation at the Piper Jaffray 29th Annual Healthcare Conference on November 28, 7:50-8:10 a.m. ET at the Lotte New York Palace in New York City (Track Seven: Kennedy 2, 4th floor). CPP CEO Jeff Jacob will give an update on the company’s pipeline including its lead Phase 3 drug CPP-1X/sul for treatment of familial adenomatous polyposis (FAP). CPP recently engaged Piper Jaffray to support its anticipated financing activities.

FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. In June, an Independent Data Monitoring Committee (IDMC) recommended continuation of the Phase 3 trial following a planned interim futility analysis. In September, the U.S. Food and Drug Administration granted CPP-1X/sul “fast track” status, potentially speeding regulatory approval and commercialization.

In 2016 CPP signed a collaboration agreement with Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) that grants Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sul in North America. Sucampo recently highlighted CPP-1X/sul during their 2017 R&D Day in New York City.

For more information on the FAP clinical trial (CPP FAP-310), please visit: https://clinicaltrials.gov/ct2/show/NCT01483144.

About Cancer Prevention Pharmaceuticals, Inc.

Cancer Prevention Pharmaceuticals, Inc. (CPP) is developing therapeutics designed to reduce the risk of cancer and other diseases. CPP’s pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neurovascular, and infectious disease. In addition to the FAP-310 trial, CPP is co-sponsoring with the National Cancer Institute (NCI) and SWOG a large Phase 3 trial in colon cancer survivors. CPP is also working collaboratively with nonprofit groups to support their clinical trials in neuroblastoma, gastric cancer, and early-onset type 1 diabetes. CPP is located in Tucson, Arizona. For more information, please visit http://canprevent.com.

For more information on the clinical trial (CPP FAP-310), please visit: https://clinicaltrials.gov/ct2/show/NCT01483144.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the benefits of Fast Track Status. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171121005238/en/

Business Wire
www.businesswire.com

Last updated on: 21/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.